Compare Tempus AI (TEM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs TG Therapeutics Inc — how do they compare? Tempus AI trades at $70.93 (market cap $12.58B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Tempus AI is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 23 Days and TG Therapeutics Inc for 16 Days on average.
| TEM | TGTX | |
|---|---|---|
Market Cap | $12.58B | $8.16B |
Volume | 7,444,569 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $96.39 | $59.06 |
52-Week Low | $41.55 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $13.21B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite negative profitability metrics. The company shows strong revenue growth (2026: $1.4B) but continues to post net losses (-$254M in 2026). Recent positive developments include FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026. Analyst consensus is strongly bullish with 64% buy ratings and a $72.60 price target, representing 4.8% upside from current levels.
The outlook remains cautiously optimistic given strong analyst support and recent business milestones, though profitability challenges and insider selling pose near-term risks. Revenue growth acceleration and AI product expansion provide potential catalysts, but investors should monitor cash burn and margin improvement progress for sustainable value creation.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
